CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04653493 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Interventions

BIOLOGICAL: CD19 CAR engineered autologous T-cells
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna

Sponsor

Sabz Biomedicals

Collaborators

[object Object]
[object Object]